Scope: KYNETIC-Liposomal azithromycin to reduce cardiac inflammation”

Grants and Contracts Details


Inflammation is a major cause of secondary injury after a heart attack that results in poor patient prognosis. Uncontrolled inflammation can cause a buildup of scar tissue and thickening of blood vessel walls. Many therapies given after a heart attack (myocardial infarction (MI)), are used to restore blood flow and prevent clotting, but none are designed to target inflammation. There is a need for a potent medication that can be used to limit cardiac inflammatory damage.
Effective start/end date5/1/206/30/21


  • KY Economic Development Cab


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.